超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

瑞士Helsinn
成立于 1976 年，總部設在瑞士，在瑞士和愛爾蘭擁有多家關聯公司，包括 Helsinn Chemicals S.A.和 Helsinn Birex Pharmaceuticals Ltd.等，共同組成HELSINN 集團。
公司策略是于初期獲取先進的專利技術，繼而進行臨床前及臨床研究的發展，并且完成藥物的研究及制藥發展后，于優勢競爭市場的國家(美國及歐洲國家)獲得市場銷售權。然后HELSINN 將產品的專利權逐步賦予其市場伙伴作分銷用途。藥品的主要成份及制成品由HELSINN 符合品質認證(GMP) 的設施制藥來供應給全球顧客。

Helsinn is a privately owned, self-financing pharmaceutical group with headquarters in Lugano, Switzerland and premises in Ireland and USA. The Helsinn Group has been built on the basis of a unique business model, focused on the in- and out-licensing of pharmaceuticals, with the recent additions of medical devices in therapeutic niche areas.

Helsinn is an important player in Cancer Supportive Care

Helsinn in-licenses early-to-late stage new chemical entities from small and big pharma companies, completes their development through the performance of preclinical and clinical studies and of chemistry, manufacturing and control (CMC) development and files and attains their market approval worldwide. The Group markets its products directly through its network of local pharmaceutical partners, selected for their deep in-market knowledge and know-how, whom Helsinn assists and supports with a full range of product and scientific management services, including commercial, regulatory, financial, legal and medical marketing advice.

The active pharmaceutical ingredients and the finished dosage products are manufactured to the highest quality, safety and environmental standards, in compliance with U.S. FDA, EU EMA, Swissmedic, Japanese PMDA and PIC requirements at Helsinn’s facilities in Switzerland and Ireland, and supplied worldwide to its customers.